Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Corless, K. Ballman, C. Antonescu, V. Kolesnikova, R. Maki, P. Pisters, M. Blackstein, C. Blanke, G. Demetri, M. Heinrich, M. Mehren, Shreyaskumar Patel, M. McCarter, K. Owzar, R. DeMatteo (2014)
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 15
M. Mehren, H. Joensuu (2018)
Gastrointestinal Stromal Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 2
C. Blanke, G. Demetri, M. Mehren, M. Heinrich, B. Eisenberg, J. Fletcher, C. Corless, C. Fletcher, P. Roberts, Daniela Heinz, Elisabeth Wehre, Z. Nikolova, H. Joensuu (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 4
Ann Oncol, 29
Critical revision of the manuscript for important intellectual content
Comprehensive Cancer Network guidelines Version 4
M. Debiec‐Rychter, R. Sciot, A. Cesne, M. Schlemmer, P. Hohenberger, A. Oosterom, J. Blay, S. Leyvraz, M. Stul, P. Casali, J. Zalcberg, J. Verweij, M. Glabbeke, A. Hagemeijer, I. Judson (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.European journal of cancer, 42 8
R. Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, Cara Beahm, B. Walters, S. Shevtsov, S. Pesant, F. Clubb, A. Rosenzweig, R. Salomon, R. Etten, J. Alroy, J. Durand, T. Force (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine, 12
Casali (2015)
Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.J Clin Oncol, 33
G. Demetri, A. Oosterom, C. Garrett, M. Blackstein, M. Shah, J. Verweij, G. McArthur, I. Judson, M. Heinrich, J. Morgan, J. Desai, C. Fletcher, S. George, C. Bello, Xin Huang, C. Baum, P. Casali (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 368
H. Joensuu, M. Eriksson, K. Hall, J. Hartmann, D. Pink, J. Schütte, G. Ramadori, P. Hohenberger, J. Duyster, S. Al-Batran, M. Schlemmer, S. Bauer, E. Wardelmann, M. Sarlomo‐Rikala, B. Nilsson, H. Sihto, O. Monge, P. Bono, R. Kallio, Aki Vehtari, M. Leinonen, T. Alvegård, P. Reichardt (2012)
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.JAMA, 307 12
H. Joensuu (2008)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor.Human pathology, 39 10
H. Joensuu, M. Eriksson, K. Hall, A. Reichardt, J. Hartmann, D. Pink, G. Ramadori, P. Hohenberger, S. Al-Batran, M. Schlemmer, S. Bauer, E. Wardelmann, B. Nilsson, H. Sihto, P. Bono, R. Kallio, J. Junnila, T. Alvegård, P. Reichardt (2016)
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 3
P. Casali, N. Abecassis, H. Aro, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J. Bovée, T. Brodowicz, J. Broto, A. Buonadonna, E. Álava, A. Tos, X. Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R. Haas, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, Robin Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D. Krákorová, A. Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A. Pousa, P. Reichardt, M. Robinson, P. Rutkowski, A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Hall, M. Unk, F. Coevorden, W. Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J. Blay (2018)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Supplement_4
R. DeMatteo, K. Ballman, C. Antonescu, R. Maki, P. Pisters, G. Demetri, M. Blackstein, C. Blanke, M. Mehren, M. Brennan, Shreyaskumar Patel, M. McCarter, J. Polikoff, B. Tan, K. Owzar (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 373
H. Joensuu, Aki Vehtari, J. Riihimäki, T. Nishida, S. Steigen, P. Brabec, L. Plank, B. Nilsson, C. Cirilli, C. Braconi, A. Bordoni, M. Magnússon, Z. Linke, J. Šufliarský, M. Federico, J. Jónasson, A. Tos, P. Rutkowski (2012)
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.The Lancet. Oncology, 13 3
G. Demetri, P. Reichardt, Yoon-Koo Kang, J. Blay, P. Rutkowski, H. Gelderblom, P. Hohenberger, M. Leahy, M. Mehren, H. Joensuu, G. Badalamenti, M. Blackstein, A. Cesne, P. Schöffski, R. Maki, S. Bauer, B. Nguyen, Jianming Xu, T. Nishida, J. Chung, C. Kappeler, I. Kuss, D. Laurent, P. Casali (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 381
Key PointsQuestionDoes administration of adjuvant imatinib for 3 years after macroscopically complete surgery prolong overall survival (OS) compared with 1-year administration in patients with localized gastrointestinal stromal tumor (GIST) with high-risk features? FindingsThis secondary analysis of a randomized clinical trial of 397 patients with high-risk GIST found that, after a median follow-up time of 10 years after the study entry, patients randomly allocated to receive 3 years of imatinib had longer recurrence-free survival and OS than patients allocated to 1 year of imatinib: Approximately one-half of deaths were avoided with the longer treatment. No new adverse safety signals were detected. MeaningThree years of treatment with adjuvant imatinib was associated with improved OS compared with 1 year of imatinib in patients with high-risk GIST.
JAMA Oncology – American Medical Association
Published: Aug 29, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.